Recombinant Adeno-Associated Viruses (rAAV) represent the primary in vivo delivery platform for approved gene therapies (such as Luxturna, Zolgensma, and Hemgenix). However, wild-type serotypes (AAV2, AAV8, AAV9) suffer from severe biological bottlenecks: heavy hepatic sequestration (liver toxicity), broad non-specific tropism, high prevalence of pre-existing neutralizing antibodies (NAbs) in up to 60% of the human population, and an inflexible 4.7 kb packaging limit.
1. Strategies for Rational & Evolutionary Capsid Modification
Modern translational gene therapy employs four primary computational and high-throughput screening methods to re-engineer the 60-subunit viral capsid protein (VP1, VP2, VP3):
- Capsid Peptide Insertion & Display: Inserting 7-to-12 amino acid targeting peptides into variable surface loops (such as loop IV at residue 588 of AAV9) to create cross-species blood-brain barrier penetrating capsids (e.g., AAV-PHP.eB, AAV-PHP.V1).
- Directed Evolution & DNA Shuffling: Generating diverse chimeric capsid libraries through error-prone PCR and multi-serotype DNA recombination, followed by rigorous in vivo selective pressure in non-human primates.
- Machine Learning & Generative Protein Design: Using deep transformer models trained on capsid fitness landscapes to generate synthetic viral capsids that share less than 70% sequence identity with wild-type serotypes, completely evading human humoral immune recognition.
2. Overcoming Neutralizing Antibodies (NAbs) & Innate TLR9 Activation
Pre-existing anti-AAV neutralizing antibodies immediately bind and clear intravenous vectors before cellular transduction can occur. Furthermore, high viral vector doses ($>10^{14}$ vector genomes/kg) trigger severe complement activation and innate immune sensing via Toll-Like Receptor 9 (TLR9) recognition of unmethylated CpG motifs in the viral inverted terminal repeats (ITRs).
Modern vector engineering circumvents immune toxicity by CpG-depleting the vector genome (silently mutating all CG dinucleotides to eliminate TLR9 engagement) and transiently pre-treating patients with IgG-cleaving endopeptidases (such as Imlifidase) to clear circulating neutralizing antibodies immediately prior to vector infusion.